Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007–2013) von Vodicka, E, Kim, K, Devine, E.B, Gnanasakthy, A, Scoggins, J.F, Patrick, D.L

Volltext

OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) von Gnanasakthy, A, DeMuro, C

Volltext

Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures von Hirsch, J. D., Gnanasakthy, A., Lale, R., Choi, K., Sarkin, A. J.

Volltext

FDA PATIENT-REPORTED OUTCOME LABELING OF NOVEL THERAPIES (2011-2015) von Gnanasakthy, A, Mordin, M, Haydysch, E, DeMuro, C

Volltext

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer von Wainberg, Z.A., Enzinger, P.C., Qin, S., Yamaguchi, K., Wang, J., Zhou, X., Gnanasakthy, A., Taylor, K., Yusuf, A., Majer, I., Jamotte, A., Kang, Y.-K.

Volltext

Patient-Reported Outcomes: Are They Worth It? An Examination in Pro Value Through Case Studies von DeMuro, C, Gnanasakthy, A

Volltext

Development Of A Disease Model For Sporadic Inclusion Body Myositis (Sibm) von Gnanasakthy, A, DeMuro, C, Lewis, S, Tseng, B

Volltext

Benefits of patient-reported outcomes in Dermatology Drug Development von Copleymerriman, C, Zelt, S, Clark, M, Gnanasakthy, A

Volltext

P1717: HEALTH‐RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH‐RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED IN A PHASE 2 C... von Spira, A., Liao, L., Zhou, X., Gnanasakthy, A., Chen, L., Ungar, D., Yu, E., Kilavuz, T., Radford, J., Hamadani, M.

Volltext

AB0504 Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab von Gnanasakthy, A., Kosinski, M., Genovese, M., Mallya, U., Mpofu, S.

Volltext

AB0506 Enhanced improvement in fatigue from RA treatment with secukinumab: An application of IRT methodology von Gnanasakthy, A., Kosinski, M., Durez, P., Mallya, U., Mpofu, S.

Volltext

AB0505 Enhanced improvement in physical functioning with secukinumab treatment among RA patients: An application of IRT methodology von Gnanasakthy, A., Kosinski, M., Kellner, H., Mallya, U., Mpofu, S.

Volltext

AB0507 Health-related quality of life (HRQOL) benefits associated with reductions in disease activity and pain severity among rheumatoid arthritis (RA) patients treated with secuki... von Gnanasakthy, A., Kosinski, M., Genovese, M., Mallya, U., Mpofu, S.

Volltext

Correlations Between Changes in the Urticaria Activity Score (UAS7) and the Dermatology Life Quality Index (DLQI) from Baseline to 28 or 40 Weeks: Comparisons of Trajectories of Ch... von Stull, D.E, McBride, D, Balp, M.M, Gnanasakthy, A

Volltext

A Novel Measure To Assess Self-Reported Physical Functioning In Patients With Sporadic Inclusion Body Myositis (Sibm) von DeMuro, C, Lewis, S, Pax Lowes, L, Alfano, L, Tseng, B, Gnanasakthy, A

Volltext

Inclusion of Patient-Reported Outcome Measures In Registered Clinical Trials: Evidence From Clinicaltrials.Gov (2007-2013) von Vodicka, E, Kim, K, Devine, B, Gnanasakthy, A, Scoggins, J, Patrick, D.L

Volltext

A Review Of Patient-Reported Outcome Orphan Drug Labels In The United States From January 2006-September 2013: Analysis Of Evidence For Orphan Drug Pro Label Claims von Clark, M, Simons, C, Haydysch, E, DeMuro, C, Gnanasakthy, A

Volltext

PCR74 Trends in the Inclusion of Patient Reported Outcomes in Oncology Clinical Trials: Analysis of ClinicalTrials.gov (2013-2022) von Mordin, M., Castro, C., Gnanasakthy, A.

Volltext

PIH54 Promotion of Patient Reported Outcomes (PRO) Label Claims Based on Non-Primary Endpoints von Gnanasakthy, A, Sadrick, A, Demuro, C, Rahul, R

Volltext

PRM38 Validation of New Measures of Patients' Post-Transplant Experience in the Patientslikeme® Organ Transplant Community von Massagli, M.P, Gnanasakthy, A, Wicks, P

Volltext